RELAPSE MULTIPLE MYELOMA
Clinical trials for RELAPSE MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSE MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for RELAPSE MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cocktail of drugs aims to tackle returning myeloma
Disease control Recruiting nowThis study tests a combination of four drugs—selinexor, carfilzomib, isatuximab, and dexamethasone—in people whose multiple myeloma has come back or stopped responding to treatment. The trial has two parts: first, a small safety run-in to find the right dose, then a larger group …
Matched conditions: RELAPSE MULTIPLE MYELOMA
Phase: PHASE1, PHASE2 • Sponsor: Natalie Callander • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New vaccine boosts CAR-T power against bone marrow cancer
Disease control Recruiting nowThis early-stage trial tests whether adding a personalized cancer vaccine (made from a patient's own immune cells and tumor cells) to standard CAR-T cell therapy can safely improve outcomes for people with multiple myeloma that has returned or stopped responding to treatment. Abo…
Matched conditions: RELAPSE MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: David Avigan • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New Vaccine-Drug combo takes on Hard-to-Treat myeloma
Disease control Recruiting nowThis early-phase study tests whether combining a personalized cancer vaccine (made from a patient's own tumor and immune cells) with the drug elranatamab is safe and feasible for people with multiple myeloma that has returned or stopped responding to prior treatments. Up to 25 pa…
Matched conditions: RELAPSE MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: David Avigan • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New drug aims to keep myeloma in check after CAR-T
Disease control Recruiting nowThis phase 2 study tests whether the drug elranatamab can lower the chance of multiple myeloma worsening after treatment with idecabtagene vicleucel (a CAR-T cell therapy). The study will enroll 32 adults with relapsed or refractory multiple myeloma. Participants will receive elr…
Matched conditions: RELAPSE MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Double-Barreled CAR-T attack on Hard-to-Treat myeloma shows promise
Disease control Recruiting nowThis study is testing a new type of CAR-T cell therapy that targets two proteins (CD19 and BCMA) on myeloma cells. It is for people whose multiple myeloma has come back or stopped responding to other treatments. The goal is to see if this dual-target approach is safe and can shri…
Matched conditions: RELAPSE MULTIPLE MYELOMA
Phase: NA • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New combo therapy takes on tough myeloma
Disease control Recruiting nowThis early-phase study tests a two-step treatment for people with multiple myeloma that has come back or stopped responding to other therapies. First, patients receive talquetamab, a drug that helps the immune system attack cancer cells. Then, they get an infusion of their own ge…
Matched conditions: RELAPSE MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New drug cocktail aims to tackle Hard-to-Treat myeloma
Disease control Recruiting nowThis Phase 2 study tests a combination of four drugs—belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone—in people with multiple myeloma that has returned or stopped responding to treatment. The goal is to see if this mix can shrink tumors or slow the disease. Abou…
Matched conditions: RELAPSE MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Can a mouth rinse save your taste buds during cancer treatment?
Symptom relief Recruiting nowThis study tests whether certain mouth rinses or oral medications can prevent or reduce taste changes caused by the drug talquetamab, used to treat multiple myeloma. About 210 participants will be randomly assigned to different preventive treatments. The goal is to find a way to …
Matched conditions: RELAPSE MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC